ACOR Acorda Therapeutics Inc.

10.85
-0.29  -3%
Previous Close 11.14
Open 11.06
Price To Book 0.84
Market Cap 516822466
Shares 47,633,407
Volume 634,339
Short Ratio
Av. Daily Volume 871,524

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Ampyra
Improve walking in patients with multiple sclerosis
Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
CVT-427
Migraine
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
FDA Approval announced December 22, 2018.
INBRIJA (CVT-301)
OFF episodes of Parkinson’s disease (PD)
Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.
BTT1023
Primary Sclerosing Cholangitis

Latest News

  1. Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled for May 2, 2019
  2. Acorda to Gain From Inbrija Sales and Neurological Pipeline
  3. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  4. Acorda to Present New Long-Term Data for INBRIJA™ (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting
  5. Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound?
  6. Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know
  7. Should You Be Concerned About Acorda Therapeutics, Inc.’s (NASDAQ:ACOR) ROE?
  8. Acorda Therapeutics Announces Management Changes
  9. Acorda to Present at Oppenheimer’s 29th Annual Healthcare Conference
  10. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR)
  11. Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape
  12. Acorda Therapeutics Announces Commercial Launch of INBRIJA™ (levodopa inhalation powder)
  13. Acorda Therapeutics to Present at Cowen Annual Health Care Conference
  14. Acorda Therapeutics to Present at Leerink Global Healthcare Conference
  15. Edited Transcript of ACOR earnings conference call or presentation 14-Feb-19 9:30pm GMT
  16. Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
  17. Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript
  18. Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates
  19. Acorda: 4Q Earnings Snapshot
  20. Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2018